The use of 1.16 mg/kg (one third) of the recommended dose of diminazene aceturate, administered indiscriminately to cattle on day seven of the unfrozen <em>Babesia bovis</em> and <em>Babesia bigemina</em> bivalent live blood vaccine reaction, was an infection and block treatment method of immunisation used successfully with no known adverse effect on the parasites or the development of protective immunity. Continuing with this practice after replacement of the unfrozen vaccine with deep-frozen monovalent <em>B. bovis</em> and <em>B. bigemina</em> live blood vaccines resulted in reports of vaccine failure. Laboratory investigation indicated the harmful effect of block treatment in preventing the development of durable immunity against <em>B. bigemina</em> as opposed to the much lesser effect it had on <em>B. bovis</em>. Consequently the practice was no longer recommended. A <em>B. bovis</em> vaccination attempt aimed at controlling the disease of dairy cows in milk (<em>n</em> = 30) resulted in 20% fatalities during the expected vaccine reaction period. The practice of block treating <em>B. bovis</em> was therefore reinvestigated, this time in a field trial using dairy cattle in milk (<em>n</em> = 11). Using 0.88 mg/kg (one quarter) of the recommended dose of diminazene administered on day 12 of the <em>B. bovis</em> vaccine reaction resulted in only two animals (<em>n</em> = 5) testing ≥ 1/80 positive with the indirect fluorescent antibody test (IFAT) although parasites could be demonstrated in three. In the untreated control group, by contrast, five of the vaccinated animals (<em>n</em> = 6) tested ≥ 1/80 positive with IFAT and parasites could be demonstrated in all. The unsatisfactory outcome obtained in this study, combined with that of the earlier investigation, indicated that there are more factors that influence successful vaccination than previously considered. It is therefore concluded that block treatment of the live frozen South African cattle babesiosis vaccines reactions is not recommended.